---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-10-11T20:05:42.095279'
end_time: '2026-10-11T20:09:45.181122'
duration_seconds: 243.09
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Brain Small Vessel Disease 2B, Autosomal Recessive
  mondo_id: MONDO:0980747
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 58
reference_validation:
  total_references: 20
  verified: 20
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 20
  on_topic: 2
  off_topic: 2
  off_topic_references:
  - DOI:10.3389/frdem.2023.1146055
  - PMC:PMC11285548
  needs_review: true
  validator_version: 0.3.0
term_validation:
  total_terms: 33
  verified: 25
  not_found: 0
  obsolete: 0
  unverifiable: 8
  confabulation_rate: 0.0
  unresolvable_prefixes:
  - Gene
  - UniProt
  - Taxon
  - MGI
  - OMIM
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Brain Small Vessel Disease 2B, Autosomal Recessive
- **MONDO ID:** MONDO:0980747 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Brain Small Vessel Disease 2B, Autosomal Recessive** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Brain small vessel disease 2B, autosomal recessive: disease-characteristics report

**Brain small vessel disease 2B (BSVD2B) is a rare, early-onset disorder associated with biallelic variants in *COL4A2*, which encodes the α2 chain of basement-membrane collagen IV.** Reported presentations range from severe fetal brain injury to childhood developmental impairment, epilepsy and motor disability. The human evidence remains a small set of families and cases; findings from the broader, predominantly *heterozygous* *COL4A2* disease spectrum must not be treated as measured frequencies or proven mechanisms of BSVD2B. **BSVD2B is not CARASIL:** CARASIL is an *HTRA1*-related disorder. [35][61][63][16]

### Evidence and provenance

| Evidence item | Publication date and URL | What it establishes |
|---|---|---|
| Bakhtiari *et al.*, **PMID: 33912663** | April 22, 2021; https://pubmed.ncbi.nlm.nih.gov/33912663/ | **Human clinical:** two affected siblings with homozygous *COL4A2* p.Gly1158Arg, epilepsy and spastic cerebral palsy. The authors concluded: “Our results indicate that both dominant and recessive forms of *COL4A2* disease exist.” [91] |
| Nicita *et al.*, **PMID: 36603335** | Online December 31, 2022; February 2023 issue; https://pubmed.ncbi.nlm.nih.gov/36603335/ | **Human clinical:** a second recessive family, described in the abstract as having “leukoencephalopathy with spot-like calcifications.” [61] |
| McNeilly *et al.*, **PMID: 39216230** | Online August 30, 2024; https://pubmed.ncbi.nlm.nih.gov/39216230/ | **Mouse, human-cell and human-tissue experiments:** reduced collagen IV, vascular remodeling and altered endothelial calcium-dependent signaling in broader *COL4A1/COL4A2* small-vessel disease—not a direct demonstration in BSVD2B patients. [85] |
| Muhammad *et al.*, **PMID: 41499643** | Online August 13, 2025; February 2026 issue; https://pmc.ncbi.nlm.nih.gov/articles/PMC12779229/ | **Human clinical and computational:** a severely affected fetus and a child with biallelic variants; extends the reported spectrum to fetal hemorrhagic injury and cortical malformations. [63] |
| Tambala *et al.*, **PMID: 40616396** | Online July 2, 2025; https://pubmed.ncbi.nlm.nih.gov/40616396/ | **Expert consensus:** evaluation and management guidance for *COL4A1/COL4A2*-related disorders collectively; not a BSVD2B-specific therapeutic trial. [199][167] |

These are **published, aggregated disease-level observations**, not an extract of individual patients’ electronic health records (EHRs). An additional 2026 retrospective EHR cohort concerns childhood-onset *COL4A1/COL4A2* disorders generally and does **not** identify how many of its ten *COL4A2* patients had biallelic disease. [35][207]

## 1. Disease information

| Identifier or name | BSVD2B entry |
|---|---|
| Preferred name; synonym | Brain small vessel disease 2B, autosomal recessive; **BSVD2B**. [35] |
| Disease ontology | **MONDO:0980747**. [35][44] |
| OMIM phenotype | **621414**; distinguish from *COL4A2* **gene** OMIM **120090**. [35][106] |
| NCBI MedGen | **C6065929**, UID **1896158**. [35] |
| Orphanet, ICD-10/ICD-11, MeSH | A **BSVD2B-specific** identifier was not established from the consulted resources. The subject headings assigned to a relevant paper, such as *Cerebrovascular Disorders* and *Leukoencephalopathies*, are **not** disease-specific BSVD2B identifiers. [21][61] |
| Important distinction | **BSVD2A** denotes the autosomal-dominant *COL4A2* phenotype, OMIM **614483**; BSVD2B denotes the biallelic phenotype. [39][35] |

The defining clinical description is neurologic abnormality beginning in infancy or the first years of life—developmental delay, impaired cognition or speech, seizures and sometimes spastic quadriplegia—with variable white-matter, ventricular, atrophic or vascular-injury findings on imaging. The later fetal report shows that *COL4A2*-associated injury can also be detected before birth. [35][63]

## 2. Etiology: causes, risks, protection and interactions

**Established cause:** disease-associated **homozygous or compound-heterozygous germline *COL4A2* variants**, ordinarily inherited one from each parent. The α2(IV) protein contributes to collagen-IV basement membranes; disruption provides a biologically plausible link to fragile or dysfunctional developing cerebral vessels. Variant effects differ, and a predicted effect in one family must not automatically be assigned to every allele. [91][63][106]

| Factor | BSVD2B-specific assessment |
|---|---|
| Genetic risk and family history | Having two relevant *COL4A2* alleles is the central risk. Consanguinity helped expose homozygosity in the original Iranian family; a later affected child had two variants inherited from nonconsanguineous parents. [91][63] |
| Age, sex and ancestry | Fetal and childhood presentations are documented in both sexes. Published case geography is **not** evidence of an ancestry-specific incidence or sex ratio. [91][63] |
| Environmental cause; infection | No toxin, occupation, diet, pathogen or infectious transmission has been established as a cause of **BSVD2B**. [35][91][63] |
| Plausible aggravating exposures | Hypertension, smoking, anticoagulation and head trauma are concerns in the **broader collagen-IV angiopathy** literature. Applying risk-reduction guidance to BSVD2B is prudent clinical extrapolation, not a measured gene–environment effect in recessive cases. [167][81] |
| Protective variants or modifiers | No validated BSVD2B-protective allele, modifier gene or epigenetic modifier was identified. Healthy heterozygous parents in reported families support recessive inheritance in those families but do not prove that every carrier is symptom-free. [91][63] |
| Gene–environment interaction | No BSVD2B-specific interaction has been quantified. A structurally vulnerable vessel might be more susceptible to blood-pressure or trauma-related injury; that final proposition is **inference**. [167][91] |

## 3. Phenotypes and effects on functioning

**Frequency rule:** the published recessive cases were ascertained for clinical abnormalities and are too few and heterogeneous for reliable population percentages. “Reported” below means observed in a cited person or family; it does **not** mean that all affected individuals develop the feature. HPO identifiers are **suggested annotation terms**, not independently measured frequencies. [91][61][63]

| Phenotype type and finding | Onset, severity, course and frequency evidence | Function or quality-of-life implications; suggested HPO |
|---|---|---|
| Developmental sign: global developmental delay and intellectual impairment | Infancy/early childhood; severe in the original two siblings, variable across later reports; **frequency undetermined**. [91][63] | Limits learning and independence; **HP:0001263**, **HP:0001249**. [91][154] |
| Communication sign: poor, delayed or absent speech | The original siblings did not speak at assessment; later children had delayed or markedly impaired language. **Frequency undetermined**. [91][63] | Major communication and caregiving impact; **HP:0001344**, **HP:0000750**. [195][190] |
| Motor signs: axial hypotonia, spasticity, quadriplegia or asymmetric hemiplegia | Childhood; ranges from inability to sit or walk to asymmetric impairment. The boy in the 2021 family was bedridden at age eight; his sister began independent walking at three. **Frequency undetermined**. [91][63] | Mobility, positioning and personal-care needs vary substantially; **HP:0008936**, **HP:0001257**, **HP:0002510**, **HP:0002301**. [160][124][182] |
| Clinical symptom: epilepsy | Focal seizures began at **six months** and **18 months** in the two original siblings; drug-resistant epilepsy was reported in the 2023 child. Not present in every later reported child. [91][63] | Seizure safety, schooling and care burden; **HP:0007359** for focal-onset seizures. [131] |
| Imaging signs: colpocephaly, porencephalic cyst and cerebral atrophy | The 2021 boy had bilateral colpocephaly; his sister had porencephaly and generalized cortical atrophy. Imaging patterns are **variable**, not diagnostic alone. [91] | May accompany motor, visual and cognitive disability; **HP:0030048** and **HP:0002132** are suitable terms for the first two findings. [187][181] |
| Imaging signs: leukoencephalopathy and intracranial calcifications | Reported in the 2023 recessive family; calcifications and white-matter injury were also described in the later fetal case. **Frequency undetermined**. [61][63] | Markers of brain injury rather than patient-reported symptoms; **HP:0002352**, **HP:0002514**. [130] |
| Imaging signs: fetal hemorrhagic injury, periventricular leukomalacia and cerebellar disruption | Severe prenatal abnormalities reported in one later fetus; **not established as universal**. [63] | Potentially profound developmental consequences; annotate hemorrhage with **HP:0002170** when its anatomical designation fits the finding. [122] |
| Cortical malformations: schizencephaly and polymicrogyria | Reported in a later child with biallelic variants; authors describe an expanded spectrum. [63] | May compound motor and developmental impairment; **HP:0010636**, **HP:0002126**. [127][123] |
| Visual or ocular signs: cortical visual impairment, nystagmus, ophthalmoplegia and strabismus | Particular reported patients, **not** a uniform syndrome. A homozygous *COL4A2* variant was also found in a study of optic-nerve hypoplasia, but that finding alone does not define typical BSVD2B. [91][63][120] | Can restrict visual access to learning and mobility; record each observed sign separately rather than assuming eye disease in every case. [91][63] |

No BSVD2B-specific **EQ-5D, SF-36 or PROMIS** result was identified. The functional descriptions above are clinical interpretations of reported abilities, not questionnaire scores. [91][63]

## 4. Genetic and molecular information

*COL4A2* is at **13q34** (**HGNC:2203; NCBI Gene:1284; Ensembl:ENSG00000134871; UniProt:P08572**). **NM_001846.4** is the reference transcript used in the later variant report. Its product is the collagen-IV α2 chain; α2(IV) assembles with two α1(IV) chains into a basement-membrane heterotrimer. **COL4A1 is its assembly partner, not a second established causal gene for BSVD2B.** [106][63][136][174]

| Reported *COL4A2* variant, NM_001846.4 | Origin, evidence and interpretation |
|---|---|
| **c.3472G>C, p.(Gly1158Arg)** | Homozygous in the two 2021 siblings; their clinically unaffected parents carried the variant. A glycine substitution in the collagen triple-helix repeat was predicted to destabilize collagen; it was absent from the population databases checked by those authors. **No direct assay of this family’s mutant protein was reported.** [91] |
| **c.535C>T, p.(Arg179Cys)** **and** **c.2069G>T, p.(Gly690Val)** | Reported **in trans** in the 2023 child with leukoencephalopathy and spot-like calcifications; both were described as rare or absent in the cited gnomAD assessment. Their combined clinical interpretation must not be assumed to apply to either allele alone. [61][71][63] |
| **c.535C>T, p.(Arg179Cys)**, homozygous | Reported in a fetus with severe abnormalities and inherited from unaffected heterozygous parents. **Important classification conflict:** the 2025/26 paper itself labels this allele **“likely benign”** under its ACMG assessment while proposing a possible hypomorphic contribution on computational grounds. Do **not** enter it as independently proven pathogenic without further assessment. The authors reported gnomAD allele frequency **0.00001449**. [63] |
| **c.826-1G>T** and **c.4275dup, p.(Gly1426Argfs*30)** | Paternal splice-acceptor and maternal frameshift alleles, respectively, in a child with developmental impairment and cortical malformations. The authors classified each **likely pathogenic**. Abnormal splicing, truncation or nonsense-mediated decay was **predicted**, not established by a patient RNA or protein assay. [63] |
| **c.4987G>A, p.(Gly1663Ser)** | Reported homozygously in a person ascertained for optic-nerve hypoplasia. Treat as a **phenotypic-boundary observation**, not proof that optic-nerve hypoplasia is frequent in BSVD2B. [63][120] |

These are reported **germline** findings, not somatic cancer mutations. No BSVD2B-defining aneuploidy, translocation, reproducible disease-specific methylation signature or validated modifier gene was established in these reports. Gene-level structural changes or variants elsewhere in the collagen-IV spectrum should not be silently assigned to this recessive subtype. [91][63]

## 5. Environmental information

No infectious agent, toxin, radiation exposure, occupational cause or BSVD2B-specific dietary association has been demonstrated. For patients with a confirmed collagen-IV angiopathy, general expert guidance favors avoiding smoking and preventable head injury and managing hypertension; these are **complication-risk precautions extrapolated from the wider *COL4A1/COL4A2* spectrum**, not methods that prevent inheritance of BSVD2B. Vaccination has no disease-specific preventive role beyond routine care. [35][167][81]

## 6. Mechanism and pathophysiology

**Ordered causal chain — observed evidence and inference explicitly separated**

1. **Biallelic germline *COL4A2* variation leads to altered α2(IV) production, structure or availability.** A glycine substitution is predicted to disturb triple-helix assembly in the original family; predicted splice and frameshift consequences differ. **Patient-variant-specific functional confirmation is limited.** [91][63]
2. **Altered α2(IV) leads to impaired assembly, secretion or composition of the α1–α1–α2 collagen-IV basement-membrane network.** Intracellular retention and reduced secretion were demonstrated for **other *COL4A2* mutations** in cellular experiments; applying the exact magnitude of that effect to each BSVD2B allele is **inferred**. [174][106]
3. **Defective collagen-IV homeostasis branches:** **(a)** reduced or abnormal vascular basement membrane leads to altered vessel support and mechanics; **(b)** retained mutant collagen can lead to endoplasmic-reticulum stress and an unfolded-protein response. Both branches have evidence in broader collagen-IV models, but their relative contribution in **biallelic human BSVD2B** is **unresolved**. [174][85]
4. **On the vascular branch, lower collagen IV leads to altered endothelial calcium and calcium-sensitive potassium-channel activity, leading to increased endothelium-dependent hyperpolarization and smooth-muscle-mediated dilation.** This sequence was tested in **heterozygous mouse and human-cell models** in 2024; transfer to recessive patients is **inferred**. [85]
5. **Vessel dysfunction or fragility can lead to hemorrhagic injury and disturbed developing-brain tissue integrity.** The causal connection is supported by model work and by the coexistence of vascular-appearing lesions and malformations in reported humans; the exact sequence that produces an individual child’s cortical malformation is **inferred, not demonstrated**. [174][63]
6. **Fetal or early-life brain injury leads to variable white-matter and cortical abnormalities, which result in developmental, motor, speech, visual and seizure manifestations.** The abnormalities and manifestations are **human observations**; their precise patient-level mediation remains uncertain. [91][61][63]

**Upstream versus downstream:** collagen folding, secretion and extracellular-matrix organization are upstream; endothelial signaling, vessel remodeling and injury are intermediate; structural brain abnormalities and neurologic disability are downstream. The main cells implicated by experiments are **brain microvascular endothelial cells** and **vascular smooth-muscle cells**; relevant suggested annotations are **CL:2000044** and **CL:0002590**. Suitable process/component suggestions include **GO:0030198** (extracellular matrix organization), **GO:0001525** (angiogenesis, a contextual process rather than a demonstrated BSVD2B-specific cascade) and **GO:0005604** (basement membrane). Annotate the **endoplasmic reticulum** only for the experimentally supported protein-retention branch; do not annotate a proven Wnt, mTOR, immune or metabolic pathway for BSVD2B from these cases. [85][174][125][134][111]

**Research limits:** the 2025/26 fetal variant assessment used protein-structure predictions, not a demonstrated tissue mechanism. No validated BSVD2B-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, epigenomic or CRISPR-screen signature was established by the cited case studies. The 2024 vascular study is mechanistically valuable **comparative evidence**, not a BSVD2B molecular profile. [63][85]

## 7. Anatomical structures affected

| Level | Reported or implicated location; suggested ontology |
|---|---|
| Primary organ and system | **Brain**, particularly developing cerebral white matter, cortex and small-vessel environment; nervous and cerebrovascular systems. Suggested **UBERON:0000955** (brain). [91][61][63][121] |
| Particular brain sites | Periventricular white matter and lateral ventricles; reported lesions also include frontal cortex, an occipital region and cerebellum in individual cases. **Do not annotate all sites as obligatory.** [91][63] |
| Tissue and cells | Vascular basement membrane is the mechanistic tissue of interest; endothelial and vascular smooth-muscle cells are implicated experimentally. Cortical and white-matter injuries are observed downstream. [85][174][63] |
| Subcellular and extracellular sites | Extracellular basement membrane; intracellular endoplasmic reticulum in experimental collagen-retention mechanisms. [174][85] |
| Other organs | Eye findings occur in some reported people. Renal and cardiovascular surveillance is recommended across *COL4A1/COL4A2* disorders, **not** because these are established frequent BSVD2B manifestations. [91][63][167] |
| Lateralization | Both bilateral and asymmetric abnormalities are reported: bilateral colpocephaly in one sibling, right-predominant motor impairment in another, and unilateral cortical abnormalities in a later child. [91][63] |

## 8. Temporal development

The reported spectrum begins **prenatally or during infancy/early childhood**. Seizures began at six and 18 months in the original siblings; fetal imaging identified severe injury in a later report. Disability can persist through childhood and adulthood—the original sister was assessed at age 20—but a standard sequence of early, intermediate and end stages or a reliable annual progression rate has **not** been established. Epilepsy can be episodic even when developmental and structural impairments persist. Spontaneous remission of BSVD2B, a disease-specific intervention window and a prospective natural-history curve are **not documented**. [91][63]

## 9. Inheritance and population

**Inheritance is autosomal recessive for the phenotype defined here.** For two confirmed carriers of the relevant disease-causing alleles, the usual Mendelian risk for **each** pregnancy is **25% affected, 50% carrier and 25% inheriting neither familial allele**; interpretation remains variant-specific, particularly when pathogenicity is disputed. Unaffected heterozygous parents are documented, but the separate dominant *COL4A2* disease spectrum means “carrier” should not be interpreted as a universal guarantee of no clinical effect. [91][63][39]

No credible BSVD2B-specific **prevalence, annual incidence, population carrier frequency, sex ratio, founder effect or geographic risk estimate** was identified. The first affected sibling pair came from a consanguineous Iranian family; the later child with two different alleles had nonconsanguineous parents. Penetrance, anticipation and germline mosaicism have not been quantified for this recessive phenotype. [91][63]

**Do not reuse broader-cohort percentages:** a 2026 single-center EHR study included **10** childhood-onset *COL4A2* patients and reported median presentation at **0.5 years**, but did **not** establish which had biallelic variants. Its ages and symptom percentages therefore are **not BSVD2B epidemiology**. [207]

## 10. Diagnostics

| Diagnostic component | Appropriate use and limitation |
|---|---|
| Clinical recognition | Consider *COL4A2* testing in unexplained early developmental/motor impairment with epilepsy and characteristic white-matter, ventricular, hemorrhagic or cortical imaging findings; lack of one particular imaging sign does not exclude it. [91][61][63][167] |
| Neuroimaging | **Brain MRI**, including sequences sensitive to hemorrhage and white-matter injury, characterizes porencephaly, ventricular shape, leukoencephalopathy and cortical malformations. **CT** can help characterize calcifications. Broader-spectrum consensus recommends head-and-neck **MRI/MRA** at diagnosis to assess vessels. [91][61][63][167] |
| Molecular confirmation | Sequence ***COL4A2*** and determine **zygosity and parental phase**. A small-vessel-disease, epilepsy or leukodystrophy panel containing *COL4A1* and *COL4A2*, or **WES**, is reasonable for a broad presentation; **WGS** may help when a panel/exome is negative despite strong suspicion, including assessment of intronic variation. The original family was identified by WES. [91][167] |
| Variant interpretation | Assess segregation, population frequency, predicted effect and current ACMG/AMP classification; seek functional evidence when needed. **Do not resolve the p.Arg179Cys classification conflict merely by finding it in an affected fetus.** [63][91] |
| Other examinations | EEG evaluates suspected seizures; ophthalmologic assessment, blood pressure, urinalysis, kidney evaluation and selected cardiovascular testing follow broader collagen-IV consensus, with scope individualized. CK and coagulation studies may assist evaluation or differential diagnosis, **not molecular confirmation**. [91][167] |
| Usually non-primary tests | Routine karyotyping, FISH, mitochondrial or repeat-expansion testing do not confirm this sequence-level diagnosis. Chromosomal microarray may investigate an *alternative* explanation or relevant copy-number change when clinically indicated; no BSVD2B-specific yield is established. No validated liquid-biopsy or omics diagnostic signature is available. [91][63][167] |

There is **no standalone standardized BSVD2B clinical score**. Differential diagnosis includes dominant *COL4A2* disease, *COL4A1*-related disease and other causes of early brain injury or malformation; distinguishing the recessive subtype requires careful **allele interpretation and phase**, not MRI appearance alone. Related hemorrhagic or white-matter presentations warrant a broader genetic and acquired-cause evaluation. [39][91][61][167]

## 11. Outcome and prognosis

Individual outcomes span severe prenatal injury, a bedridden child, and a sister who achieved walking but had absent speech and motor disability at age 20. Focal seizures were partly controlled in the brother and controlled in the sister with reported medicines. These observations demonstrate substantial **variable morbidity**, not a calculable prognosis. No defensible BSVD2B-specific **five-year survival, mortality rate, life expectancy, validated quality-of-life score or prognostic biomarker** is available. Structural damage may require long-term habilitation; an individual recovery probability cannot be inferred from the case series. [91][63]

## 12. Treatment and current implementation

**There is no established disease-modifying treatment for BSVD2B.** Management addresses seizures, developmental and motor needs, and avoidable vascular risks; care plans should be individualized with pediatric neurology, genetics and relevant rehabilitation specialists. The 2025 consensus provides guidance for the **broader collagen-IV disorder group**, not BSVD2B treatment-response rates. Suggested **NCIT intervention annotations** below are labels to map against the current NCIT release; no unverified NCIT identifier is asserted. [91][167]

| Intervention; suggested NCIT term | Evidence, use and limits |
|---|---|
| **Antiseizure medication**; *Anticonvulsant Therapy* | In the original family, **carbamazepine** partly controlled one child’s focal seizures; **phenobarbital plus carbamazepine** controlled the sister’s seizures. These are two case observations, **not a response-rate estimate or genotype-guided regimen**. The 2023 child was reported to have drug-resistant epilepsy. [91][63] |
| **Physical, occupational and speech-language therapy**; corresponding *Physical Therapy*, *Occupational Therapy* and *Speech-Language Therapy* terms | Appropriate supportive/habilitative planning for documented mobility and communication disability; **BSVD2B-specific trial outcomes are unavailable**. [91][63] |
| **Blood-pressure and vascular-risk management**; *Blood Pressure Monitoring* | Broader *COL4A1/COL4A2* consensus advises monitoring and avoiding hypertension. Antiplatelets and anticoagulants are generally **not recommended solely for primary or secondary prevention** in this disorder group; compelling alternative indications require individualized specialist assessment. [167] |
| **Sodium 4-phenylbutyrate**; *Investigational Drug Treatment* | Chemical-chaperone work reduced hemorrhage in ***Col4a1* mutant mice**. This is **not evidence of BSVD2B clinical efficacy**: another mouse study warned that improved endoplasmic-reticulum stress did not necessarily repair mechanically defective basement membrane. It should not be presented as standard BSVD2B treatment. [139][140] |
| **Gene, cell, RNA or targeted channel therapy**; relevant experimental-intervention terms only if a study is identified | No established BSVD2B-specific efficacy, approved therapy, treatment-response rate or pharmacogenomic rule was found. The 2024 endothelial-signaling work identifies **potential targets**, not an administered clinical treatment. [85][167] |

A registered **observational**, non-drug study of *COL4A1/COL4A2*-related conditions, **NCT07374913** (https://clinicaltrials.gov/study/NCT07374913), collects multisystem assessments and exploratory MMP2/MMP9 measurements; it is **not** a BSVD2B therapeutic trial or validation of those enzymes as prognostic biomarkers. A hereditary small-vessel-disease registry, **NCT06512376** (https://clinicaltrials.gov/study/NCT06512376), also lists *COL4A1/2* among eligible genes. [168][171]

## 13. Prevention and counseling

| Prevention level | BSVD2B-appropriate interpretation |
|---|---|
| **Primary prevention of affected births** | Offer molecular diagnosis, family-specific carrier testing and genetic counseling; discuss reproductive options, including prenatal or preimplantation testing where appropriate and available. Lifestyle change cannot remove inherited biallelic variants. [91][63][167] |
| **Secondary prevention and early detection** | Cascade-test relatives when familial alleles are sufficiently classified; assess an at-risk child clinically and consider imaging according to specialist advice. There is **no established universal newborn-screening program** for BSVD2B. [167][91] |
| **Tertiary prevention** | Treat epilepsy and functional complications; manage blood pressure, avoid smoking and high-risk head trauma, and review antithrombotic decisions individually. These vascular precautions derive from wider collagen-IV guidance rather than a controlled BSVD2B prevention study. [167][91] |
| **Immunization, antimicrobial or environmental prophylaxis** | No disease-specific vaccine, antimicrobial prophylaxis, sanitation measure or toxin-removal program prevents BSVD2B. [35][91] |

## 14. Other species and naturally occurring disease

BSVD2B is a **human disease designation** (** *Homo sapiens*, NCBI Taxon:9606**). The orthologous mouse gene is ***Col4a2*** (** *Mus musculus*, Taxon:10090; NCBI Gene:12827; MGI:88455**). The zebrafish ***col4a2*** ortholog is catalogued as associated with the disease term, but that ontology association does **not** establish naturally occurring BSVD2B in fish. No spontaneous veterinary breed-specific counterpart, VBO breed identifier, zoonotic transmission or cross-species infection applies on the available evidence. [106][201][32]

## 15. Model organisms and research applications

| Model and evidence type | Recapitulation, application and limitation |
|---|---|
| **ENU-induced *Col4a2* missense mice**; animal model, **PMID:17179069** | Heterozygotes showed eye, brain, kidney, vascular-stability and viability abnormalities; reported homozygotes did not survive beyond the second trimester. Useful for collagen-IV development and vascular integrity, but **not** a surviving, genotype-matched model of every human BSVD2B allele. [130][42] |
| ***Col4a2* mutant mouse and human cell assays**; animal/in vitro, **PMID:22209247** | Other *COL4A2* mutations produced intracellular α1/α2 collagen accumulation and impaired secretion; some activated endoplasmic-reticulum stress. Supports a plausible pathway, **not direct functional proof for p.Gly1158Arg or each newer recessive allele**. [174][91] |
| **Heterozygous *Col4a2* knockout mice, mutant human brain endothelial cells and human vascular tissue**; animal/in vitro/human tissue, **PMID:39216230** | Tests collagen-IV abundance, vessel-wall mechanics and calcium-dependent endothelial signaling. **Heterozygous knockouts and sporadic-disease tissue cannot supply recessive-patient phenotype frequencies.** [85] |
| **Computational structural assessment of p.Arg179Cys**; computational, **PMID:41499643** | Generates a testable protein-stability hypothesis, but does not substitute for an RNA, secretion, basement-membrane or disease-causality assay—especially given the paper’s reported **likely-benign** classification of that allele. [63] |

**Knowledge-base curation priority:** retain **MONDO:0980747 ↔ OMIM:621414 ↔ biallelic *COL4A2*** as the disease-level association. Attach each phenotype to its **specific patient/publication**, each variant to its **phase and reported classification**, and each mechanistic claim to its **human, animal, in-vitro or computational evidence type**. Leave prevalence, penetrance, survival, BSVD2B-specific treatment efficacy and most phenotype frequencies **unquantified** rather than importing estimates from dominant or mixed-inheritance cohorts. [35][91][63][207]

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 20 |
| Resolved | 20 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 20 |
| On topic | 2 |
| Off topic | 2 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `DOI:10.3389/frdem.2023.1146055` (1 mention) - The emerging role of the HTRA1 protease in brain microvascular disease
  - shared terms: disease, brain
- `PMC:PMC11285548` (1 mention) - The emerging role of the HTRA1 protease in brain microvascular disease.
  - shared terms: disease, brain

Weighed against this report's own most characteristic terms: `bsvd2b`, `col4a2`, `bsvd2b-specific`, `variant`, `injury`, `child`, `established`, `recessive`, `clinical`, `collagen-iv`, `family`, `developmental`, `biallelic`, `allele`, `disease`, `brain`, `assessment`, `seizure`, `affected`, `epilepsy`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 33 |
| Resolved | 25 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 8 |

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `Gene`, `UniProt`, `Taxon`, `MGI`, `OMIM`.

25 of 33 terms resolved to a current term; the rest could not be looked up either way.